Results 41 to 50 of about 75,353,973 (171)

Inflammation and increased intraocular pressure associated with intravitreal aflibercept 8 mg: A systematic review and meta-analysis [PDF]

AJO International
Topic: Aflibercept 8 mg was recently approved for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Nikoline Skindhøj Rebsdorf, Marie Martine Michaelsen, Natasja Kærmose Ølholm, Suffía Olsen, Celine Lee, Yousif Subhi, Marie Ørskov, Henrik Vorum, Lasse Jørgensen Cehofski   +8 more
doaj   +2 more sources

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials

Ophthalmology and Therapy
Introduction Reducing intravitreal injection frequency while maintaining efficacy is a critical goal in alleviating the burden associated with anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema (DME) or ...
Scott M. Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, Ali Mojebi, Sam Keeping, Keith Chan, Theodore Leng, Nimesh Patel   +8 more
doaj   +2 more sources

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products

CPT: Pharmacometrics & Systems Pharmacology
Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in ...
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Torsten Zimmermann, Zhongqing Will He, John D. Davis, A. Thomas DiCioccio, Lutz O. Harnisch   +10 more
doaj   +2 more sources

The clinical utility of aflibercept for diabetic macular edema

Diabetes, Metabolic Syndrome and Obesity, 2015
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular
Stewart MW
doaj   +1 more source

Aflibercept 8 mg in Neovascular AMD—A Fast-Drying Anti-VEGF Drug: A Prospective Morpho-Functional Pilot Study [PDF]

Ophthalmology and Therapy
Introduction This study investigated early anatomical and functional outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) treated with 8 mg aflibercept compared to patients treated with the standard dose of 2 mg ...
Michele Rinaldi, Gilda Cennamo, Marina Concilio, Gaetano Corvino, Alessia Riccardo, Raffaele Nubi, Ciro Costagliola   +6 more
doaj   +2 more sources

One-Year Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in Japan: A Multicenter Retrospective Study [PDF]

Clinical Ophthalmology
Rikuto Mizuma,1,* Yuki Mizuki,1– 3,* Akihiro Kamata,4 Junji Onishi,4 Takuto Sakono,1 Misa Suzuki,1,5 Nobuhisa Mizuki1 1Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan ...
Mizuma R, Mizuki Y, Kamata A, Onishi J, Sakono T, Suzuki M, Mizuki N   +6 more
doaj   +2 more sources

Author Correction: Sustainability in medical retina: the environmental impact of using aflibercept 8 mg instead of aflibercept 2 mg in treatment-naïve patients with nAMD. [PDF]

Eye (Lond)
Bowley N, Thomas P, Sivaprasad S, Purbrick RMJ, Beardmore E, Gilbert R, Clarke A, Chase TJG.   +7 more
europepmc   +2 more sources

Early high-dose aflibercept 8 mg clinical outcomes in wet age-related macular degeneration patients resistant to aflibercept 2 mg or faricimab. [PDF]

Acta Ophthalmol
Acta Ophthalmologica, Volume 104, Issue 7, Page e885-e887, November 2026.
Sutinen P, Hecht I, Tuuminen R.
europepmc   +2 more sources

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration. [PDF]

Acta Ophthalmol
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study ...
Abu Ishkheidem I, Inci E, Breimer M, Silfverswärd ST, Zetterberg M, Grönlund MA.   +5 more
europepmc   +3 more sources

Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel. [PDF]

Eye (Lond)
Therapies with robust visual outcomes and reduced patient and healthcare system treatment burden are needed amidst the rising incidence of neovascular age-related macular degeneration (nAMD).
Gale R, Awad MH, Bailey C, Cackett P, Chhabra R, Downey L, Ghanchi F, Kotagiri A, Narendran N, Pearce I, Peto T, Sivaprasad S, Younis S, Napier J, Gilbert R, Ismat S.   +15 more
europepmc   +2 more sources